UNSPSC 51144006: Dexmethylphenidate

This classification denotes a cns stimulant with the molecular formula C14H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) M32RH9MFGP, chemically known as 2-piperidineacetic acid, alpha-phenyl-, methyl ester, threo- but more generally known as dexmethylphenidate, which bears US NIH Compound Identifier 154101. European Medicines Agency schedules Dexmethylphenidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30294.

UNSPSC 51144006 Dexmethylphenidate, a Commodity code, covers prescription pharmaceutical products state and local governments procure for health and human services operations, though recent solicitations show minimal activity specifically tied to this code. The recent state and local opportunities posted under this code do not target dexmethylphenidate directly; instead, they address broader pharmaceutical procurement—naloxone and drug deactivation systems for public health response, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals through cooperative purchasing. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participating jurisdictions). These entities are sourcing pharmaceutical products to support emergency response, pharmacy benefit management, and routine health service delivery.

Activity appears concentrated in Florida and Minnesota through cooperative purchasing mechanisms, with Texas pursuing exploratory market research on direct pharmaceutical sourcing models. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: date discrepancy in source), requiring electronic submission through the county's e-Procurement Portal and including FEMA compliance obligations. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement (MMCAP) released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across state and local facilities, with proposals due March 26, 2026, requiring cGMP and Drug Supply Chain Security Act compliance and three-wholesaler distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The code shows minimal targeted activity for dexmethylphenidate specifically.